key: cord-1009016-fhonfnxq
authors: Zhou, Jun; Le, Kehao; Xu, Ming; Ming, Jie; Yang, Wen; Zhang, Qiulei; Lu, Linlin; Xi, Zihan; Ruan, Shengnan; Huang, Tao
title: CXCR4 antagonist AMD3100 reverses the resistance to tamoxifen in breast cancer via inhibiting AKT phosphorylation
date: 2020-06-24
journal: Mol Ther Oncolytics
DOI: 10.1016/j.omto.2020.06.009
sha: e8b01048b2cf9a10a3517a57862eb5f778b04d16
doc_id: 1009016
cord_uid: fhonfnxq

Abstract Endocrine therapy is a systemic therapy and has become the main treatment strategy for patients with estrogen receptor (ER) positive breast cancer. However, tamoxifen resistance has become an insurmountable clinical challenge and the underlying mechanisms are still poorly understood. In this study, we explored the roles of CXCR4 in tamoxifen-treated breast cancer and tamoxifen resistance. Based on Gene Expression Omnibus (GEO) database, high expression of CXCR4 was found to be associated with worse overall survival (HR = 4.646, p < 0.001) and cancer-specific survival (HR = 4.480, p < 0.001) in tamoxifen-treated breast cancer. CXCR4 was also positively correlated with the level of AKT phosphorylation and the resistance to tamoxifen in breast cancer. AMD3100 is a CXCR4 antagonist and was found to decrease p-AKT levels of tamoxifen-resistant cells. The reversal effect of AMD3100 on tamoxifen resistance was also confirmed in vitro and in vivo. Taken together, our study demonstrated that CXCR4 could be a potential prognostic biomarker for tamoxifen-treated breast cancer and the combination of AMD3100 with tamoxifen could be a more efficacious therapeutic strategy for the treatment of tamoxifen resistance.

Breast cancer is the fifth leading cause of death in women and the most frequently diagnosed malignancy in women worldwide 1 . Approximately 70% of breast cancer tumors express estrogen receptor (ER) 2 . Endocrine therapy is a systemic therapy and has become the main treatment strategy for premenopausal and postmenopausal positive patients 3, 4 . Tamoxifen is the most widely studied, used and representative drug blocking ER, which has been used for advanced disease, neoadjuvant and adjuvant therapy, and chemotherapy prevention in high-risk women 5 . Despite advances in treatment, endocrine resistance is still present in a subset of patients with recurrent or metastatic disease progression after primary hormone receptor-positive breast cancer diagnosis 6 . Therefore, it is important to seek predictive biomarkers for tamoxifen-treated patients and take a deeper insight into the underlying molecular mechanisms of tamoxifen resistance.

CXC chemokine receptor type 4 (CXCR4) is a 7-transmembrane G-protein coupled receptor and promotes tumor growth, angiogenesis, and metastasis in various types of cancers [7] [8] [9] [10] . CXCR4 has been reported to be involved in a variety of intracellular signaling pathways, and overexpressed CXCR4 can activate Wnt/β-catenin, Notch, JAK/STAT, MAPKs, and PI3K/AKT pathways 11 . CXCR4 was reported to be associated with the prognosis of breast cancer patients 12 , but it remains unknown whether CXCR4 has prognostic significance in tamoxifen-treated breast cancer or how does its expression level change in tamoxifen-resistant cells. Therefore, it is meaningful to explore the relationship between CXCR4 and tamoxifen resistance in breast cancer from the perspective of clinical significance and mechanism verification. AMD3100 is a specific antagonist of CXCR4, which binds to CXCR4, inhibits the interaction between CXCR4 and CXCL12, and has no cross-reaction with other chemokine receptors [13] [14] [15] . Previous studies reported that AMD3100 could inhibit the proliferation of breast cancer cells and increase the sensitivity to radiotherapy in breast cancer in vivo 16, 17 . But whether AMD3100 could be used to reverse the resistance to tamoxifen has never been reported.

In this study, we aimed to identify a potential predictive biomarker of tamoxifen resistance and explore the role of CXCR4 in tamoxifen resistance. Using multiple gene expression analyses, we identified that high expression of CXCR4 was associated with poor prognosis in tamoxifen-treated breast cancer and CXCR4 was upregulated in tamoxifen-resistant breast cancer cells. Besides, we also demonstrated that AMD3100, a specific antagonist of CXCR4, could reverse the resistance to tamoxifen via inhibiting AKT phosphorylation.

We cultured T47D cells with 1 µM tamoxifen for more than six months to establish the tamoxifen-resistant subline T47DR as our previous study has described 18 .

Observation of morphological changes showed that T47DR cells were fusiform, which was different from T47D ( Fig. 1A-1B) . In order to verify whether T47DR cells are resistant to tamoxifen, the proliferation and apoptosis of T47D and T47DR cells treated with tamoxifen were compared by CCK8 assays and Annexin V-FITC/PI assays. The results of the CCK8 assay showed that the cell viability of T47DR cells was higher than that of T47D cells when the concentrations of tamoxifen were 5 and 10 µM (Fig. 1C) . The half maximal inhibitory concentrations (IC50) of tamoxifen were 4.47 µmol/L in T47D cells and 7.80 µmol/L in T47DR cells. The results of Annexin V-FITC/PI experiment showed that apoptosis of T47DR cells was reduced than T47D cells when treated with tamoxifen (Fig.1D) . In order to compare the gene expression profile of T47D and T47DR cells, the RNA sequencing was conducted (GSE129544). 5,123 up-regulated and 5,229 down-regulated mRNAs were identified as being differentially expressed between T47D and T47DR (Fig.1E) . To obtain an accurate and reliable result, we also conduct bioinformatic analysis based on another two GEO datasets (GSE9893 and GSE31831). The intersection of three GEO datasets contained several genes, including CXCR4. And the results showed that CXCR4 was upregulated in tamoxifen-resistant breast cancer cells MCF7R and T47DR (Fig. 1F ).

Based on dataset GSE9893, we analyzed the association between CXCR4 expression and the prognosis of 155 tamoxifen-treated breast cancer patients. We compared the CXCR4 expression in different subgroups: whether local recurrence or distant metastasis, overall death, and breast cancer-specific death occurred. The subgroups with worse outcomes had higher CXCR4 expression, respectively ( Fig. 2A, B, C) .

Then, we divided the patients into two groups according to the CXCR4 expression level for further analysis. To identify the optimal cut-off value for subdivision, we conducted a time-dependent receiver operating characteristic (ROC) curve analyses by using the "survivalROC" package in R to distinguish five-year survivors from deceased patients. In overall survival analysis, the cut-off value for CXCR4 (AUC = 0.711) was 1.405369 (Fig. 2D) . In cancer-specific survival analysis, the cut-off value for CXCR4 (AUC = 0.714) was 1.405369 (Fig. 2E ). Finally, we chose 1.405369 as the optimal cut-off value, and patients were divided into CXCR4 low and CXCR4 high groups. In the cohort of 155 tamoxifen-treated patients, patients with high CXCR4 run a higher risk of N category (p = 0.004), local recurrence or distant metastasis (p < 0.001), overall death (p < 0.001) and breast cancer-specific death (p < 0.001) ( Table 1) . Survival analyses showed CXCR4 high group was significantly associated with worse overall survival (p < 0.001, Fig. 2F ) and cancer-specific survival (p < 0.001, Fig. 2G ), respectively. The hazard ratios (HRs) for overall mortality and cancer-specific mortality were listed in Table 2 to investigate the clinical significance. Unadjusted HRs of CXCR4 for overall mortality and cancer-specific mortality were 4.646 (p < 0.001) and 4.480 (p < 0.001), respectively. Multivariate Cox analyses adjusted for age at diagnosis, T category, N category, SBR grade, and adjuvant therapy confirmed the independent prognostic significance of CXCR4 for both overall mortality (HR = 3.027, p = 0.002) and cancer-specific mortality (HR = 2.498, p = 0.031).

In order to verify the results of sequencing and bioinformatic analysis, we detected the protein and mRNA levels of CXCR4 in T47D and T47DR cell lines, and found that CXCR4 was significantly overexpressed in T47DR cells (Fig. 3A-3B ). And the phosphorylated forms of AKT (ser473) was increased in T47DR cells. Taken together, our results strongly suggested that CXCR4 was upregulated in tamoxifen-resistant T47DR cells and may play an important role in tamoxifen resistance.

Given the above results that CXCR4 was upregulated in tamoxifen-resistant cells, we then explored the potential involvement of CXCR4 in tamoxifen resistance of T47DR cells. To this end, we knocked down the expressing levels of CXCR4 in T47DR cells with exogenous introduction of CXCR4 siRNAs (CXCR4-si1, CXCR4-si2, and CXCR4-si3). Western blot and qRT-PCR assays were conducted to detect the knockdown efficiency and the results showed that CXCR4-si1 and CXCR4-si2 led to a significant reduction of CXCR4 expression in T47DR cells ( Figure 3C-3D ). There was no significant difference in total AKT but p-AKT was significantly lower along with CXCR4 knockdown compared with the control group. Then, T47DR cells transfected with CXCR4-si1 and CXCR4-si2 were selected to further investigate the effects of CXCR4 knockdown on the resistance to tamoxifen. The results of CCK8 indicated that CXCR4 knockdown reduced the resistance of T47DR cells to tamoxifen (Fig. 3E ). Besides, Annexin V-FITC/PI assay confirmed that knockdown of CXCR4 reversed the resistance to tamoxifen in T47DR cells (Fig. 3F ). These results indicated that CXCR4 knockdown led to T47DR cells re-sensitization to tamoxifen and CXCR4 is required for sustaining tamoxifen resistance in breast cancer cells.

As we have observed that knockdown of CXCR4 reversed tamoxifen resistance in T47DR cells, we used CXCR4 antagonist AMD3100 against T47DR cells overexpressing CXCR4. As shown in Fig. 4A , the phosphorylation levels of AKT were significantly down-regulated when T47DR cells were treated with AMD3100.

The results of CCK8 assay indicated that AMD3100 reversed the resistance of T47DR cells to tamoxifen (Fig. 4B) . Furthermore, Annexin V-FITC/PI assay confirmed that AMD3100 reduced the resistance to tamoxifen in T47DR cells (Fig. 4C ). By means of synergistic or additive inhibitory effects, AMD3100 was capable of enhancing the activity of tamoxifen on tamoxifen-resistant breast cancer cells in vitro via inhibiting AKT phosphorylation. To evaluate whether AMD3100 can reverse the resistance to tamoxifen in vivo, we injected the T47DR cells into the dorsal flank of female nude mice to construct a murine breast cancer xenograft model. 15 days after injecting, we divided the tumor-bearing mice into 2 groups: tamoxifen plus PBS treated group and tamoxifen plus AMD3100 treated group. Each group was comprised of 5 mice and all the mice were treated for 24 days. Tumor growth curves showed that tumor progression was significantly slowed in mice treated with tamoxifen plus AMD3100 compared with another group (Fig. 4D ), but there was no significant difference in body weight (Fig. 4E) . The isolated tumors were weighed and tamoxifen plus AMD3100 treated group had lighter tumors compared to the control group (Fig.   3F&3G ). Besides, we used H&E, Ki67 and CXCR4 staining to investigate the pathological and proliferation status of these tumors. Compared with the control group, AMD3100 inhibited the function of CXCR4, increased the necrosis of tumor cells, and decreased the expression of Ki67 (Fig. 4H ). In brief, the animal experiments suggested that the combination of tamoxifen and AMD3100 could effectively reverse tamoxifen resistance, but without significant side effects in vivo.

Tamoxifen, as an effective endocrine therapy, significantly improves the prognosis of patients with estrogen receptor-positive breast cancer 19 . However, the resistance to tamoxifen makes it difficult for some breast cancer patients to get a good prognosis.

Studies reported that several components were overexpressed or activated in tamoxifen-resistant breast cancer 20, 21 . The AKT/mTOR signaling pathway is one of the alternative oncogenic signaling pathways which are often activated in endocrine-resistant breast cancer. Two different endocrine therapy strategies are being adopted to tamoxifen resistance: enhancement of endocrine therapy, and the combination of endocrine therapy and other inhibitors of components that mediate endocrine resistance 3 . A phase II clinical trial showed that mTOR inhibitor Everolimus significantly improved the efficacy of letrozole in neoadjuvant therapy for ER-positive breast cancer 22 . However, there are always many twists and turns in the process of new drug development. Many clinical trials of inhibitors against endocrine therapy of breast cancer, such as AZD8931, Ganitumab, and Selumetinib, have failed [23] [24] [25] . Therefore, the exploration of mechanisms of resistance, the search for new therapeutic targets, and the development of new drugs are still of great significance for the treatment of tamoxifen-resistant breast cancer.

CXCR4 encodes a CXC chemokine receptor specific for stromal cell-derived factor-1.

It is well known for its earlier role as a coreceptor for HIV entry 26 . In addition to CXCL12, the only known chemokine that binds CXCR4, extracellular ubiquitin also acts as an immune regulator through CXCR4-mediated signal transduction 27, 28 . When CXCL12 combines with CXCR4, various downstream signaling pathways are activated, resulting in various reactions such as intracellular calcium content increase, gene transcription, chemotaxis, cell survival, and proliferation 29 . Some recent studies have reported the relationship between CXCR4 and the estrogen-dependent tumor progression. ER could promote the expression of CXCR4 when ER combined with estrogen, and the combination of CXCR4 and CXCL12 could also promote the expression of ER 30, 31 . These findings suggest that the interaction between CXCR4 and ER may be a key mechanism of tumor progression in ER-positive breast cancer. In addition, tamoxifen has also been found to inhibit the expression of CXCR4, which may be one of the mechanisms by which tamoxifen could inhibit the proliferation of ER-positive breast cancer cells 32 . Though some studies have found that CXCR4 can promote the progress of ER-positive breast cancer, these studies cannot explain the relationship between CXCR4 and estrogen-independent tumor progression. Lyndsay v.

Rhodes et al. reported that CXCR4 could mediate estrogen-independent tumor progression of breast cancer, and suggested that CXCR4 might be associated with the resistance to endocrine therapy in breast cancer 32 .

Furthermore, AMD3100 was shown to specifically inhibit CXCR4-mediated events 15 .

A previous study 33 reported that CXCR4 promotes tamoxifen resistance via AhR signaling, but the prognostic significance and the expression differences of CXCR4

were not found. We further explored the role of CXCR4 in tamoxifen resistance and found the effect of CXCR4 on the AKT signaling pathway, as well as the inhibitory effect of AMD3100 on AKT phosphorylation and tamoxifen resistance from another perspective. The results of this study showed that CXCR4 exhibited differential expression levels in three datasets from GEO database. Based on the clinical information of GSE9893, high expression of CXCR4 was found to be associated with poor prognosis in tamoxifen-treated breast cancer and a good prognostic indicator of these patients. Cell experiments showed that CXCR4 promoted tamoxifen resistance through AKT pathway and might be a potential predictive biomarker of tamoxifen resistance. Besides, CXCR4 antagonist AMD3100 reversed the resistance to tamoxifen in breast cancer via inhibiting AKT phosphorylation. As mentioned above, the combination of endocrine therapy and other inhibitors of components that mediate endocrine resistance is one of the suggested strategies for endocrine therapy-resistant breast cancer. The combination of tamoxifen and AMD3100 could increase tumor-suppressing effects and reduce the potential side effects caused by drug dosage.

We observed no significant side effects of the combination, particularly in the body weight of nude mice. However, the more detailed mechanisms by which CXCR4 promotes tamoxifen resistance and AMD3100 reverses tamoxifen resistance have not been studied deeply, and we aim to further explore the downstream molecules that are regulated by CXCR4 and its antagonist AMD3100 in tamoxifen-resistant breast cancer in future studies.

In conclusion, our results will help us to further understand the mechanisms of how CXCR4 mediated the biological process of tamoxifen resistance in breast cancer. We demonstrated that AMD3100 is capable of improving the efficacy of tamoxifen treatment by inhibiting the hyperphosphorylation of AKT in tamoxifen-resistant breast cancer. Our findings provide the feasibility for using the combination of tamoxifen and AMD3100 as a more efficacious therapeutic strategy in the treatment of tamoxifen-resistant breast cancer.

ER-positive breast cancer cells T47D were purchased from the American Type Culture Collection (ATCC, USA) and 4-Hydroxytamoxifen was purchased from Sigma-Aldrich (H7904, USA). To establish the tamoxifen-resistant subline T47DR, T47D cells were treated with 1 µM 4-Hydroxytamoxifen continuously and cultured in RPMI 1640 medium (Gibco, USA) supplemented with 10% fetal bovine serum (Gibco, USA) and 1% penicillin/streptomycin (Beyotime, China) in a humidified condition containing 5% CO 2 at 37 °C for more than six months. After six months, the resistance of T47DR cells to tamoxifen was verified by CCK8 assay. AMD3100 was purchased from Selleck (Shanghai, China) and dissolved in phosphate buffer saline (PBS)

High-throughput sequencing was performed using T47D and T47DR cell lines. 

To evaluate the response of different cell lines to tamoxifen treatment, a Cell Count Kit 8 (CCK8) assay was also performed according to the manufacturer's protocol.

Different cells were seeded into 96 well plates at a density of 5,000 cells/well with different concentrations of tamoxifen or AMD3100 and then cultured for 48 hours.

Subsequently, RPMI-1640 containing 10% CCK 8 solution (Dojindo, Japan) was supplemented into each well and incubated in a 37°C incubator for 1-3 hours. The spectrometric absorbance of each well at 450 nm was measured on a microplate reader (Thermo Fisher, USA) to evaluated the cytotoxicity of tamoxifen to cell lines.

Annexin V FITC Apoptosis Kit (556547, BD, USA) was used to determine the apoptotic cells according to the manufacturer's instruction. Cells in the logarithmic growth phase were collected and seeded into 6-well plates in triplicates and then treated with 5 µM tamoxifen for 24 hours. In the antagonist function experiment, 10 µM AMD3100 or PBS was used in combination with tamoxifen. Finally, we used a flow cytometer (Beckman Coulter, Fullerton, CA, USA) to identify apoptotic cells.

The total protein of cells was isolated with protein extraction reagent RIPA buffer 

Total RNA was extracted from cultured cells using RNAiso Plus reagent (TaKaRa, Japan) according to the manufacturer's protocol. mRNAs were reverse-transcribed to cDNAs with a PrimeScript RT Master Mix Kit (TaKaRa, Japan). Quantitative and then injected into the flanks of mice. The health status of nude mice was recorded every three days, and the tumor size was measured. From the 15th day after the inoculation of tumor cells, each nude mouse was given 10 mg/kg tamoxifen by oral gavage every day. All the mice were divided into two groups randomly and administered intraperitoneally every 2 days: 1) 5 mg/kg of AMD3100 dissolved in 100µl PBS, 2) 100 µl PBS alone. 39 days after injection, mice were killed and the tumor was removed from the back and weighed.

The primary antibodies against CXCR4 (Proteintech, China) and anti-Ki67 (Novocastra, UK) were used for IHC analyses. IHC was performed as previously described 34 . In addition, the slide was stained with hematoxylin and eosin (H&E).

SPSS 23.0, R 3.5.3, and Graphpad Prism 7.0 were used for statistical analysis. The experiment data are presented as the means ± standard deviations (SD). Differences between groups in CCK8 assay were analyzed by the Student's t or Two-way ANOVA test. Survival rates of patients were estimated using the Kaplan-Meier method and differences between groups were assessed using the log-rank test. Cox proportional hazard regression model was used to analyze the prognostic significance of CXCR4.

P-value less than 0.05 was considered statistically significant.

S.R. and T.H. designed the experiments. J.Z. and K.L. conducted the experiments, contributed to data analysis and the revision of the manuscript. J.Z., Q.Z., and L.L.

contributed to bioinformatics analysis. J.Z., W.Y. and Z.X. conducted the animal assays. All authors read and approved the final manuscript.

The authors declare no competing interests.

Our research was supported by National Natural Science Foundation of China (Grants: 81672611). Thanks to all those who contributed to this research. We thank the Chinese government and citizens for their quick response to the COVID-19 outbreak and generous support to the healthcare system in Wuhan, China. With their help, the situation in Wuhan has been improved quickly, and we had enough time and energy to revise this article.

The high-throughput sequencing data (GSE129544, GSE9893, and GSE31831) used to support the findings of this study are included in the article or GEO database. Morphological differences between T47D and T47DR cells. (C) CCK-8 assay showed that the cell proliferation ability of T47DR was higher than that in T47D when they were treated with tamoxifen. (D) Annexin V-FITC/PI assay showed the difference of apoptosis between T47D and T47DR cells when they were treated with 5 µM tamoxifen. (E) Differentially expressed genes in T47D and T47DR cells. (F) The intersection of the three datasets (GSE9893, GSE31831 and GSE129544). CXCR4 was upregulated in tamoxifen-resistant breast cancer cells MCF7R and T47DR. TAM, tamoxifen. Differences between groups in CCK8 assay were analyzed by the Student's t test. Error bars represent means ± SD of triplicate. *p < 0.05, **p < 0.01, ***p < 0.001. Western blot (A) and qRT-PCR (B) confirmed CXCR4 overexpression in tamoxifen-resistant breast cancer cells T47DR. CXCR4 was significantly down-regulated in T47DR cells after transfection with CXCR4-si1 and CXCR4-si2 detected by western blot (C) and qRT-PCR (D). (E) CCK8 assay showed that CXCR4 knockdown reversed the resistance of T47DR cells to tamoxifen. (F) Annexin V-FITC/PI assay showed that CXCR4 knockdown increased the apoptosis of T47DR cells treated with tamoxifen. Differences between groups were analyzed by the Student's t or Two-way ANOVA test. Error bars represent means ± SD of triplicate. *p < 0.05, **p < 0.01, NS: not significant. Figure 4 : AMD3100 overcomes tamoxifen resistance via inhibiting AKT phosphorylation. (A) p-AKT was significantly down-regulated in T47DR cells after T47DR cells were treated with AMD3100 for 24 hours. (B) CCK8 assay showed that AMD3100 reversed the resistance of T47DR cells to tamoxifen. (C) Annexin V-FITC/PI assay showed that AMD3100 increased the apoptosis of T47DR cells treated with tamoxifen. (D, E, F, G) Compared to the other groups, the TAM + AMD3100 treated mice had significantly smaller tumors, but there was no significant difference in body weight. (H) Compared with the control group, AMD3100 inhibited CXCR4, increased the necrosis of tumor cells, and decreased the expression of Ki67. TAM, tamoxifen. Differences between groups were analyzed by the Student's t or Two-way ANOVA test. Error bars represent means ± SD of triplicate. *p < 0.05, **p < 0.01, ***p < 0.001, NS: not significant. 

CXCR4 is a good prognostic indicator of tamoxifen-treated breast cancer and promotes the resistance to tamoxifen. CXCR4 antagonist AMD3100 can reverse the resistance to tamoxifen by inhibiting the hyperphosphorylation of AKT. Tao Huang and colleagues provide the feasibility of the combination of tamoxifen and AMD3100 in tamoxifen-resistant breast cancer.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer

Endocrine treatment in breast cancer: Cure, resistance and beyond

Molecularly targeted endocrine therapies for breast cancer

PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy. Breast cancer research and treatment

The intricate role of CXCR4 in cancer

Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis

CXCR4 and cancer

The role of CXC chemokines and their receptors in cancer. Cancer letters

CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug design, development and therapy

Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis

The bicyclam AMD3100 story

Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor

Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4

CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients

High expression of TRAF4 predicts poor prognosis in tamoxifen-treated breast cancer and promotes tamoxifen resistance. Anti-cancer drugs

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. The New England journal of medicine

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08

HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor

Modulation of the CXC chemokine receptor 4 agonist activity of ubiquitin through C-terminal protein modification

CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin

The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways

Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells

Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway

Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer

CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling

A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1